22nd Century Group, Inc (NASDAQ:XXII) Sees Large Increase in Short Interest

22nd Century Group, Inc (NASDAQ:XXII) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 257,129 shares, a growth of 52.9% from the December 15th total of 168,162 shares. Based on an average daily volume of 147,874 shares, the short-interest ratio is presently 1.7 days. Approximately 3.4% of the shares of the company are short sold. Approximately 3.4% of the shares of the company are short sold. Based on an average daily volume of 147,874 shares, the short-interest ratio is presently 1.7 days.

22nd Century Group Price Performance

Shares of 22nd Century Group stock opened at $0.85 on Friday. 22nd Century Group has a 52-week low of $0.75 and a 52-week high of $149.50. The firm has a market capitalization of $6.49 million, a PE ratio of -0.01 and a beta of 1.00. The company’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.94.

22nd Century Group (NASDAQ:XXII) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($16.79) by $15.73. 22nd Century Group had a negative net margin of 37.64% and a negative return on equity of 184.33%.

Institutional Investors Weigh In On 22nd Century Group

An institutional investor recently raised its position in 22nd Century Group stock. Anson Funds Management LP lifted its stake in 22nd Century Group, Inc (NASDAQ:XXII) by 197.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,212 shares of the biotechnology company’s stock after buying an additional 65,174 shares during the period. Anson Funds Management LP owned about 1.41% of 22nd Century Group worth $166,000 at the end of the most recent reporting period. Institutional investors own 18.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on XXII shares. Wall Street Zen raised 22nd Century Group from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of 22nd Century Group in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.